Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Katarzyna Sobańska"'
Autor:
Edyta Szałek, Agnieszka Karbownik, Tomasz Grabowski, Katarzyna Sobańska, Anna Wolc, Edmund Grześkowiak, Joanna Stanisławiak-Rudowicz
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resistant thyroid carcinoma. Neoplastic diseases are the cause of pain, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb69af2aa7351c70828f7a6a803bf1a7
https://doi.org/10.1007/s00280-020-04075-3
https://doi.org/10.1007/s00280-020-04075-3
Autor:
Tomasz Grabowski, Anna Wolc, Agnieszka Karbownik, Anna Stachowiak, Katarzyna Sobańska, Edmund Grześkowiak, Hanna Urjasz, Edyta Szałek, Agnieszka Szczecińska, Joanna Stanisławiak-Rudowicz
Publikováno v:
Pharmacological Reports
Background Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9efcfc64d468cb4c6b3f65bd58cd46cd
http://europepmc.org/articles/PMC8187206
http://europepmc.org/articles/PMC8187206
Autor:
Włodzimierz Płotek, Szymon Plewa, Agnieszka Klupczynska, Agnieszka Karbownik, Katarzyna Sobańska, Edmund Grześkowiak, Tomasz Grabowski, Edyta Szałek
Publikováno v:
Investigational New Drugs
SummaryBackground Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC). The ATP-binding ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759d686c03ecba4e6af6b8fc9642a951
https://doi.org/10.1007/s10637-019-00806-3
https://doi.org/10.1007/s10637-019-00806-3
Autor:
Zuzanna Synowiec, Katarzyna Sobańska, Tomasz Synowiec, Artur Teżyk, Piotr Tomczak, Anna Jabłecka
Publikováno v:
Clinical genitourinary cancer. 20(4)
There are known correlations between axitinib exposure and treatment response. The aim of the article was to study relationships between the axitinib steady-state trough concentration and the treatment efficacy and toxicity.35 patients (24 men and 11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0536a2d6aed78c3220d5d7c45b1ae9c
https://pubmed.ncbi.nlm.nih.gov/35428585
https://pubmed.ncbi.nlm.nih.gov/35428585
Autor:
Anna Wolc, Marta Moch, Katarzyna Sobańska, Agnieszka Karbownik, Tomasz Grabowski, Edyta Szałek, Szymon Plewa, Agnieszka Klupczynska, Zenon J. Kokot, Edmund Grześkowiak
Publikováno v:
Pharmacological Reports. 70:191-195
Background Diabetes mellitus (DM) is a complex metabolic disorder which affects the function of numerous tissues and alters the pharmacokinetic parameters of many drugs. As many oncological patients are diabetics, it is important to determine the inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::befd3657b823f5d64ec20aa235afb4cc
https://doi.org/10.1016/j.pharep.2017.09.003
https://doi.org/10.1016/j.pharep.2017.09.003
Autor:
Katarzyna Sobańska, Magdalena Magiera, Zenon J. Kokot, Edmund Grześkowiak, Agnieszka Karbownik, Szymon Plewa, Joanna Porażka, Edyta Szałek, Agnieszka Klupczynska, Anna Wolc, Tomasz Grabowski
Publikováno v:
Investigational New Drugs
Summary Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk of dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abb3e1c9403b74f542695368956c8713
https://doi.org/10.1007/s10637-018-0573-1
https://doi.org/10.1007/s10637-018-0573-1
Autor:
Katarzyna Sobańska, Edmund Grześkowiak, Tomasz Grabowski, Edyta Szałek, Agnieszka Karbownik, Anna Wolc
Publikováno v:
European Journal of Pharmaceutical Sciences. 102:55-62
Background Erlotinib is a tyrosine kinase inhibitor available for the treatment of non-small cell lung cancer. Paracetamol is an analgesic agent, commonly used in cancer patients. Because these drugs are often co-administered, there is an increasing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d10d467f9970d2740569a3307d27eab
https://doi.org/10.1016/j.ejps.2017.02.028
https://doi.org/10.1016/j.ejps.2017.02.028
Autor:
Katarzyna Sobańska, Tomasz Grabowski, Anna Stachowiak, Hanna Urjasz, Agnieszka Szczecińska, Agnieszka Karbownik, Edyta Szałek, Anna Wolc, Joanna Stanisławiak-Rudowicz, Edmund Grześkowiak
Publikováno v:
Pharmacological Reports
Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f787673a4c8a0b2a94d2b9a2d534d7
https://doi.org/10.1007/s43440-021-00278-4
https://doi.org/10.1007/s43440-021-00278-4
Autor:
Edmund Grześkowiak, Edyta Szałek, Anna Wolc, Tomasz Grabowski, Katarzyna Sobańska, Agnieszka Karbownik
Publikováno v:
Pharmacological Reports. 68:964-968
Background Alterations in blood glucose levels observed in diabetes, may change the pharmacokinetics of co-administered drugs and in consequence, the efficacy and safety of therapy. Many oncological patients are diabetics and it is important to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf2c184e22cfc511a3971146c7d77aa
https://doi.org/10.1016/j.pharep.2016.04.015
https://doi.org/10.1016/j.pharep.2016.04.015
Autor:
Katarzyna Sobańska, Wojciech Połom, Małgorzata Lewandowska, Tomasz Grabowski, Marcin Matuszewski, Edmund Grześkowiak, Agnieszka Karbownik, Anna Wolc, Edyta Szałek
Publikováno v:
Pharmacological Reports. 66:892-896
Background Diabetes is one of the most common metabolic diseases in the world, which may influence changes in the pharmacokinetics and pharmacodynamics of drugs. Sunitinib is a tyrosine kinase inhibitor (TKI) broadly used for treatment of numerous ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42a5e0b12d165f8a02efea4509d51cb
https://doi.org/10.1016/j.pharep.2014.05.011
https://doi.org/10.1016/j.pharep.2014.05.011